Get the Stockscreener App
18.81
2.64%
-0.51
After Hours:
18.81
Enliven Therapeutics Inc stock is traded at $18.81, with a volume of 409.29K.
It is down -2.64% in the last 24 hours and down -6.23% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$19.32
Open:
$19
24h Volume:
409.29K
Relative Volume:
0.84
Market Cap:
$922.99M
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-9.9524
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-14.31%
1M Performance:
-6.23%
6M Performance:
-13.95%
1Y Performance:
-28.70%
1-Day Range:
$18.53
$19.44
1-Week Range:
$18.53
$22.45
52-Week Range:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
18.81 | 1.14B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
How Enliven Therapeutics Inc. stock performs during market volatilityFree Low Volatility Stable Growth Picks - Newser
Forecasting Enliven Therapeutics Inc. price range with options dataGrowth Based Investment Plan Guidance Highlighted - metal.it
Real time social sentiment graph for Enliven Therapeutics Inc.Low Exposure Strategy with Sector Analysis - Newser
Pattern recognition hints at Enliven Therapeutics Inc. upsideDividend Strategy Summary With 10-Year Outlook - Newser
Published on: 2025-07-30 13:46:37 - beatles.ru
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionFree Fast Entry High Potential Stock Alerts - Newser
Can volume confirm reversal in Enliven Therapeutics Inc.AI-Based Reversal Point Prediction Signal - Newser
What makes Enliven Therapeutics Inc. stock price move sharplyDaily Upside Movement Prediction With Data - Newser
Short Term Trend Reversal in Enliven Therapeutics Inc. PossibleAccurate Technical Trend Reversal Picks Detected - metal.it
Using economic indicators to assess Enliven Therapeutics Inc. potentialWeekly Hot Stocks Based on Volume Flow - Newser
Can Enliven Therapeutics Inc. rally from current levelsFree High Conviction Intraday Stock Signals - Newser
Is Enliven Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsidePortfolio Positioning Strategy With Timing - Newser
Breakout Traders Target Enliven Therapeutics Inc. on Recovery SetupBuy Signal Based on Chart Analysis Confirmed - metal.it
Is it the right time to buy Enliven Therapeutics Inc. stockGet exclusive market analysis for investors - jammulinksnews.com
Is Enliven Therapeutics Inc. a growth stock or a value stockRecord-breaking capital gains - jammulinksnews.com
Can Enliven Therapeutics Inc. rally from current levels Free Real Time Alerts Based on AI Prediction - Newser
What are the latest earnings results for Enliven Therapeutics Inc.Invest smarter with expert trading signals - jammulinksnews.com
Should I hold or sell Enliven Therapeutics Inc. stock in 2025Invest confidently with actionable market data - jammulinksnews.com
How does Enliven Therapeutics Inc. generate profit in a changing economyStay informed with expert market forecasts - jammulinksnews.com
What is the risk reward ratio of investing in Enliven Therapeutics Inc. stockNavigate market shifts with confidence - jammulinksnews.com
What catalysts could drive Enliven Therapeutics Inc. stock higher in 2025High-profit stock alerts - jammulinksnews.com
Sectors Driving Future Growth for Enliven Therapeutics Inc. StockWeekly Double Return List - Newser
Is Enliven Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Trading Group - Newser
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Position Trimmed by New York State Common Retirement Fund - Defense World
What drives Enliven Therapeutics Inc. stock priceTremendous wealth creation - PrintWeekIndia
What risks could impact Enliven Therapeutics Inc. stock performanceMarket-beating returns - jammulinksnews.com
Will Enliven Therapeutics Inc. stock split in the near futureMoney Making Low Risk Plans - Newser
Polis encourages life-sciences companies to move to Colorado - BizWest
Enliven Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Autocar Professional
BlackRock, Inc. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus
What analysts say about Enliven Therapeutics Inc. stockOutstanding investment returns - Autocar Professional
Is Enliven Therapeutics Inc. a good long term investmentTriple-digit growth rates - Autocar Professional
Enliven Therapeutics CSO sells $278k in shares By Investing.com - Investing.com Canada
Enliven Therapeutics CSO sells $278k in shares - Investing.com Australia
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):